期刊文献+

高锰酸钾氧化水中沙拉沙星的动力学研究 被引量:3

Kinetics study on sarafloxacin oxidization by permanganate in aqueous environment
下载PDF
导出
摘要 选用高锰酸钾为氧化剂从动力学的角度研究高锰酸钾初始浓度,p H值和温度对沙拉沙星氧化反应速率的影响,并比较高锰酸钾氧化其他氟喹诺酮类药物(恩诺沙星,氧氟沙星,环丙沙星,诺氟沙星)的动力学参数,旨在为沙拉沙星污染治理提供科学依据和建议.研究得出:氧化过程符合二级反应动力学规律,随着高锰酸钾浓度和环境温度的升高,反应速率增加;相对于中性条件和碱性条件[K=30~47L/(mol·min)],酸性条件(p H=4~5)下其反应速率[K=66~91.28L/(mol·min)]要明显更快.高锰酸钾氧化沙拉沙星的动力学参数与环丙沙星的类似,在相关研究中可以适当参考环丙沙星的处理参数. By evaluating the effects of initial concentration of KMnO4, pH and temperature, experimental studies ofsarafloxacin oxidation kinetics by potassium permanganate were investigated. Meanwhile, the kinetics parameters of otherfluoroquinolones (e.g. enrofloxacin, ofloxacin, ciprofloxacin, norfloxacin) were compared with those of sarafloxacin, thusproviding a feasible approach for degradation and removal of sarafloxacin in the aquatic environment. The resultsindicated that the kinetic rate of sarafloxacin oxidization by potassium permanganate in the aqueous solution followed thesecond-order kinetics model. An increase in the initial KMnO4 concentration or temperature corresponded to an increasein the reaction rate. Furthermore, the reaction rate [K=66-91.28L/(mol·min)] under acidic conditions (pH=4-5) wasobviously higher than that [K=30-47L/(mol·min)] under the neutral and alkaline conditions. The kinetic parameters ofsarafloxacin were similar to those of ciprofloxacin, which could be validated for the determination of relevant parametersof sarafloxacin.
出处 《中国环境科学》 EI CAS CSSCI CSCD 北大核心 2018年第3期917-922,共6页 China Environmental Science
基金 国家水体污染控制与治理科技重大专项(2014ZX07405002)
关键词 沙拉沙星(SAR) 氟喹诺酮类抗生素 氧化 高锰酸钾 动力学 sarafloxacin (SAR) fluoroquinolones oxidation potassium permanganate kinetics
  • 相关文献

参考文献2

二级参考文献45

  • 1李镜明,蒋海涛.富营养化水源的给水除臭技术[J].中国给水排水,1994,10(1):33-37. 被引量:8
  • 2徐维海,张干,邹世春,李向东,刘玉春.香港维多利亚港和珠江广州河段水体中抗生素的含量特征及其季节变化[J].环境科学,2006,27(12):2458-2462. 被引量:141
  • 3王学军,许振良,杨座国,邴乃慈.水相识别分子印迹技术[J].化学进展,2007,19(5):805-812. 被引量:15
  • 4Wakefield B. Fluorinated Pharmaceuticals [ J ]. lnnov. Pharmaeeut. Tech, 2000, 74- 78.
  • 5Siewert S. Validation of a levofloxacin HPLC assay in plas- ma and dialysate [ J]. J Pharm Biomed Anal, 2006, 41 (4) : 1360 - 1362.
  • 6Martinez M, McDermott P, Walker R. Pharmacology of the fluoroquinolones: A perspective for the use in domestic ani- mals[J]. Vet J,2006, 172: 10-28.
  • 7Ansari J. Dnag interaction and pharmacist [ J ]. J Young Pharm, 2010, 2(3): 326-331.
  • 8Andreu V, Blasco C, Pic6Y. mine quinolone residues [ J ] 2007, 26(6) : 534 -556.
  • 9Analytical strategies to deter- TrAC Trend Anal Chem, Speltini A, Sturini M, Maraschi F, et al. Analytical meth- ods for the determination of fluoroquinolones in solid envi- ronmental matrices[ J]. TrAC Trends Anal Chem, 2011 , 30 (8) : 1337 - 1350.
  • 10Moema D, Nindi M M, Dube S. Development of a disper- sive LLME method for the determination of fluoroquinolones in chicken liver by HPLC [ J]. Anal Chim Acta, 2012, 730 : 80 - 86.

共引文献3

同被引文献25

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部